GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
The Effects of Ganglioside-Monosialic Acid in Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer: A Randomized Trial
Sponsor: Sun Yat-sen University
Terminated
Difficulty accruing subjects the study accrual was closed
Other terminated trials from Sun Yat-sen University
Other Breast Cancer trials with similar outcome
A PHASE3 clinical study on Breast Cancer and Chemotherapy-Related Cognitive Impairment, this trial is terminated or withdrawn. The trial is conducted by Sun Yat-sen University and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE3
Status: Unknown → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
First recorded
Feb 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .